1,024 material Form 8-K filings that 799 companies we cover made with the SEC in August 2025, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Bristow Group reported second quarter 2025 revenues of $376.4 million, net income of $31.7 million, or $1.07 per diluted share, and Adjusted EBITDA of $60.7 million, all up from the first quarter. The company raised its 2025 Adjusted EBITDA outlook to $240 million to $260 million and its 2026 outlook to $300 million to $335 million, and it began accelerated debt payments and share repurchases.
Q2 2025 total revenues were $376.4 million, up from $350.5 million in Q1 2025.
Net income was $31.7 million, or $1.07 per diluted share, compared with $0.92 per diluted share in Q1 2025.
Adjusted EBITDA outlook raised to $240 million to $260 million for 2025 and $300 million to $335 million for 2026.
Repurchased 119,841 shares for $3.9 million and made $15.3 million of accelerated principal payments on its UKSAR Debt facility in the quarter.
ONE Gas reported second-quarter 2025 net income of $32.0 million, or $0.53 per diluted share, up from $27.2 million, or $0.48, a year earlier. It raised its 2025 diluted EPS guidance to $4.32 to $4.42 from $4.20 to $4.32, and declared a $0.67 quarterly dividend, which benefits shareholders by lifting expected full-year earnings.
Q2 2025 net income was $32.0 million, or $0.53 per diluted share, versus $27.2 million, or $0.48, in Q2 2024.
Year-to-date 2025 net income was $151.5 million, or $2.51 per diluted share, versus $126.6 million, or $2.23, in the same period of 2024.
2025 net income guidance was raised to $261 million to $267 million, from $254 million to $261 million.
Board declared a $0.67 per share quarterly dividend, payable September 3, 2025, to holders of record on August 18, 2025.
LeMaitre Vascular reported preliminary second-quarter 2025 results, with net sales of $64.2 million, up 15%, and diluted earnings per share of $0.60, up 16%. The company raised its full-year 2025 sales and earnings guidance, now projecting sales of $248 million to $254 million and diluted EPS of $2.23 to $2.37. The results are preliminary and unaudited.
Q2 2025 gross margin was 70.0%, up from 68.9% a year earlier, and operating income was $16.1 million, up 12%.
Full-year 2025 guidance: sales of $248 million to $254 million and EPS of $2.23 to $2.37.
Q3 2025 guidance: sales of $61.2 million to $63.2 million and EPS of $0.54 to $0.59.
Board approved a $0.20 per share quarterly dividend, payable September 4, 2025, to holders of record on August 21, 2025.
Supernus reported second-quarter 2025 total revenues of $165.5 million, down 2% from $168.3 million a year earlier, while diluted earnings per share rose to $0.40 from $0.36 and net earnings were $22.5 million. It raised full-year 2025 revenue guidance to $670 million-$700 million and moved its GAAP operating earnings guidance to a loss of $70 million-$80 million, citing the Sage Therapeutics acquisition completed July 31, 2025. For shareholders, quarterly profit improved, but revenue slipped and the GAAP operating outlook worsened.
Q2 2025 total revenues were $165.5 million, versus $168.3 million in Q2 2024; Qelbree net sales rose 31% to $77.6 million.
Q2 2025 net earnings were $22.5 million, or $0.40 per diluted share, versus $0.36 a year earlier; six-month diluted EPS was $0.19 versus $0.36.
Full-year 2025 total revenue guidance is $670 million-$700 million, up from $600 million-$630 million.
Full-year 2025 GAAP operating earnings (loss) guidance is $(70) million to $(80) million, down from $(15) million to $10 million.
Assurant reported second quarter 2025 GAAP net income of $235.3 million, up 25 percent from $188.7 million a year earlier, and GAAP diluted EPS of $4.56, up from $3.58. The company raised its full-year 2025 outlook, now expecting adjusted EPS excluding reportable catastrophes to approach 10% growth, and plans $250 to $300 million in share repurchases at the upper end of its guidance.
Q2 2025 adjusted EPS was $5.10 versus $4.08; excluding reportable catastrophes, it was $5.56 versus $4.77.
First-half 2025 GAAP net income fell 10 percent to $381.9 million, with reportable catastrophes of $186.8 million pre-tax versus $58.7 million a year earlier.
Global Housing Adjusted EBITDA rose 33 percent to $214.4 million in Q2; Global Lifestyle rose 6 percent to $201.4 million.
Holding company liquidity was $518 million as of June 30, 2025, and $225 million remains under the current repurchase authorization.
DoubleVerify reported second-quarter 2025 revenue of $189.0 million, up 21% from a year earlier, with net income of $8.8 million compared with $7.5 million in the prior-year quarter. The company raised its full-year 2025 revenue growth guidance to approximately 15% and reaffirmed its adjusted EBITDA margin guidance of approximately 32%.
Q2 2025 revenue was $189.0 million, up 21%; Activation revenue rose 25%, Measurement 15%, and Supply-side 26%.
Q2 net income was $8.8 million, or $0.05 per diluted share, versus $7.5 million, or $0.04 per diluted share, a year earlier.
Q2 adjusted EBITDA was $57.3 million, a 30% margin, versus $46.8 million a year earlier.
Third-quarter 2025 guidance calls for revenue of $188 million to $192 million and adjusted EBITDA of $60 million to $64 million.
Qualys reported second-quarter 2025 revenue of $164.1 million, up 10% from a year earlier, and GAAP diluted earnings of $1.29 per share, up from $1.17. The company raised its full-year 2025 revenue and per-share earnings guidance, which is favorable for shareholders, though operating cash flow fell 32% in the quarter.
Q2 2025 revenue $164.1 million, up 10% from $148.7 million; GAAP diluted EPS $1.29 vs. $1.17; non-GAAP diluted EPS $1.68 vs. $1.52
Full-year 2025 revenue guidance raised to $656.0 million to $662.0 million from $648.0 million to $657.0 million
Full-year 2025 GAAP EPS guidance raised to $4.47 to $4.77 from $4.27 to $4.57; non-GAAP EPS guidance raised to $6.20 to $6.50 from $6.00 to $6.30
Q2 operating cash flow fell 32% to $33.8 million from $49.8 million
LGI Homes reported second-quarter 2025 home sales revenues of $483.5 million, down from $602.5 million a year earlier, and net income of $31.5 million, or $1.36 per diluted share, versus $58.6 million, or $2.48, in the prior-year quarter. The company withdrew its full-year 2025 guidance and issued outlook only for the third quarter, citing limited visibility into the fourth quarter for its spec-focused model.
Q2 2025 home sales revenues were $483.5 million, versus $602.5 million in Q2 2024; home closings were 1,323, versus 1,655.
Q2 2025 net income was $31.5 million, or $1.36 diluted EPS, versus $58.6 million, or $2.48, a year earlier.
The company withdrew full-year 2025 guidance and expects third-quarter 2025 closings between 1,100 and 1,300.
The company repurchased 367,568 shares for $20.6 million in Q2 2025; total liquidity was $322.6 million at June 30, 2025.
Knife River reported second-quarter 2025 revenue of $833.8 million, up 3%, but net income fell 35% to $50.6 million and diluted EPS fell to $0.89 from $1.37. The company revised full-year 2025 adjusted EBITDA guidance to $475 million to $525 million, citing wet weather, weak demand in Oregon and July flooding in Texas, which matters to shareholders because it reflects a weaker outlook for the year.
Q2 revenue $833.8 million, up 3% from $806.9 million; adjusted EBITDA $140.8 million, down 9%
Net income $50.6 million versus $77.9 million a year earlier; diluted EPS $0.89 versus $1.37
Record backlog of $1.3 billion at June 30, 2025, up nearly 30% from a year earlier
Full-year 2025 adjusted EBITDA guidance set at $475 million to $525 million
Frontdoor reported second-quarter 2025 revenue up 14% to $617 million and net income up 21% to $111 million, with diluted EPS of $1.48 versus $1.18. The company raised its full-year 2025 revenue, gross profit margin and Adjusted EBITDA ranges and increased its 2025 share repurchase target to approximately $250 million.
Q2 2025 revenue $617 million, up 14%, with 2-10 acquisition a main driver of volume growth
Diluted EPS $1.48 versus $1.18 a year earlier; Adjusted EBITDA $199 million, up 26%
Full-year 2025 Adjusted EBITDA range raised to $530 million to $550 million; revenue range raised to $2.055 billion to $2.075 billion
Share repurchases totaled $150 million year-to-date through July 2025; 2025 target raised to approximately $250 million
Enpro reported second-quarter 2025 sales of $288.1 million, up 6.0%, while net income was $26.4 million versus $26.7 million a year earlier and adjusted diluted EPS fell 2.4% to $2.03. The company raised its full-year 2025 guidance, now expecting adjusted EBITDA of $270 million to $280 million and adjusted diluted EPS of $7.60 to $8.10, compared with prior ranges of $262 million to $277 million and $7.00 to $7.70. Higher sales were offset by growth-related operating expenses and foreign exchange headwinds, so shareholders see revenue and guidance improving alongside lower quarterly profit.
Q2 2025 sales of $288.1 million, up 6.0%; adjusted EBITDA of $71.1 million versus $74.0 million, down 3.9%
Diluted EPS of $1.25 versus $1.27; adjusted diluted EPS of $2.03 versus $2.08
Full-year 2025 adjusted EBITDA guidance raised to $270 million-$280 million from $262 million-$277 million
Quarterly dividend of $0.31 per share declared July 31, 2025, payable September 17, 2025
Life Time Group Holdings reported second-quarter 2025 revenue of $761.5 million, up 14.0% from a year earlier, and net income of $72.1 million, up 36.6%. The company raised its full-year 2025 revenue and net income guidance, with revenue now expected at $2,955 million to $2,985 million, which signals stronger expected profitability for shareholders.
Q2 diluted EPS was $0.32, up 23.1% from $0.26 a year earlier; adjusted diluted EPS was $0.37, up 48.0%.
Full-year 2025 revenue guidance is $2,955 million to $2,985 million, up from $2,940 million to $2,980 million; net income guidance is $290 million to $293 million.
Net debt leverage ratio improved to 1.8 times as of June 30, 2025, from 3.0 times a year earlier.
Q2 net income included a $9.0 million tax-effected net loss on a sale-leaseback transaction and $9.3 million in tax-effected employee retention credit proceeds.
Pediatrix Medical Group reported second-quarter 2025 net income of $39.3 million, or $0.46 per diluted share, compared with a net loss of $153.0 million a year earlier, which included impairment charges. Net revenue fell to $468.8 million from $504.3 million, mainly due to practice dispositions, and the company raised its full-year 2025 Adjusted EBITDA outlook to a range of $245 million to $255 million from $220 million to $240 million.
Q2 2025 net revenue was $468.8 million, down from $504.3 million in Q2 2024, mainly due to practice dispositions.
Q2 2025 net income was $39.3 million, or $0.46 per diluted share, versus a net loss of $153.0 million in Q2 2024.
Q2 2025 Adjusted EPS was $0.53, compared with $0.34 a year earlier.
Full-year 2025 Adjusted EBITDA outlook raised to $245 million to $255 million from $220 million to $240 million.
Ball Corporation reported second quarter 2025 results, with U.S. GAAP net sales of $3.34 billion and total diluted earnings per share of 76 cents, up from $2.96 billion and 51 cents a year earlier. The company raised its full-year guidance for comparable diluted earnings per share growth to 12-15% and said it expects to return at least $1.5 billion to shareholders in 2025.
Q2 2025 U.S. GAAP net earnings attributable to Ball were $212 million, or 76 cents per diluted share, versus $158 million, or 51 cents, in Q2 2024.
Q2 2025 comparable diluted EPS was 90 cents, versus 74 cents in Q2 2024; comparable net earnings were $249 million.
Full-year 2025 guidance for comparable diluted EPS growth was increased to 12-15%.
Ball returned $1.13 billion to shareholders in the first six months of 2025 and expects to return at least $1.5 billion by year-end.
Amneal Pharmaceuticals reported second-quarter 2025 net revenue of $725 million, up 3% from a year earlier, and GAAP net income attributable to the company of $22 million, up from $6 million. The company raised its full-year 2025 adjusted EBITDA and adjusted diluted EPS guidance, while keeping net revenue guidance unchanged, and completed a debt refinancing that it says extends maturities to 2032.
Q2 2025 net revenue was $725 million, up 3% from $702 million; GAAP diluted EPS was $0.07 versus $0.02, and adjusted diluted EPS was $0.25, up 56%.
Adjusted EBITDA was $184 million, up 13% from the second quarter of 2024.
2025 guidance: adjusted EBITDA raised to $665 million-$685 million from $650 million-$675 million; adjusted diluted EPS raised to $0.70-$0.75 from $0.65-$0.70; net revenue unchanged at $3.0 billion-$3.1 billion.
On August 1, 2025, the company completed $2.1 billion of new seven-year Term B loans and $600 million of 6.875% senior secured notes due 2032, used to refinance prior debt.
Edgewell Personal Care reported third-quarter fiscal 2025 net sales of $627.2 million, down 3.2%, with adjusted EPS of $0.92 versus $1.22 a year earlier. The company lowered its full-year fiscal 2025 outlook, including adjusted EPS of about $2.65 versus a prior range of $2.85 to $3.05, citing weak Sun Care seasons, tariffs and foreign exchange, which points to lower profit and cash generation for shareholders this year.
Q3 net sales were $627.2 million, down 3.2%; organic net sales fell 4.2% and North America organic sales fell 8.0%.
Q3 GAAP diluted EPS was $0.62 versus $0.98, and adjusted EPS was $0.92 versus $1.22 in the prior year quarter.
FY2025 adjusted EPS is now expected to be about $2.65 (previously $2.85 to $3.05); GAAP EPS is now about $1.73 (previously $2.09 to $2.29).
FY2025 free cash flow is now expected to be about $80 million (previously $130 million to $140 million); the board declared a $0.15 quarterly dividend payable October 8, 2025.
DuPont reported second quarter 2025 net sales of $3.3 billion, up 3%, adjusted EPS of $1.12, up 15%, and GAAP income from continuing operations of $238 million, up 35%. The company raised its full-year 2025 guidance, including adjusted EPS of about $4.40, and said the raise more than offsets the estimated $20 million tariff impact. Operating cash flow from continuing operations fell 28% to $381 million, and the planned Qnity electronics spin-off remains on track for November 1, 2025.
Q2 2025 net sales of $3.3 billion rose 3%; organic sales rose 2%
Full-year 2025 guidance: adjusted EPS of about $4.40, net sales of about $12.85 billion, operating EBITDA of about $3.36 billion
Cash provided by operating activities from continuing operations was $381 million, down from $527 million a year earlier
Electronics spin-off (Qnity) targeted for November 1, 2025
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.